Array BioPharma to Present at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Confere

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Stifel Nicolaus Healthcare Conference and the Rodman & Renshaw Global Investment Conference. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.

   

Event:

Stifel Nicolaus Healthcare Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Thursday, September 18, 2011

Time:

11:30 a.m. Eastern Time

Location:

Four Seasons, Boston, MA

Webcast:

www.arraybiopharma.com

 

Event:

Rodman & Renshaw Global Investment Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Monday, September 12, 2011

Time:

10:50 a.m. Eastern Time

Location:

The Waldorf=Astoria, New York, NY

Webcast:

www.arraybiopharma.com

 

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.